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Progress in understanding steps in viral leukemogenesis has often come from 
the  study  of mouse  strains  resistant  to  the  development  of leukemia.  This 
approach has led to the identification of mouse genes controlling replication of 
input leukemia viruses (Fv-1  [1], Fv-4 [2]),  replication of defective transforming 
viruses  (Fv-2 [3,  4]),  susceptibility to  virus-induced immunosuppression  (Fv-3 
[5]), and immune response to virus or leukemic cell antigens (H-2 [6], H-2-1inked 
genes Rfv-1 [7] and Rfv-2 [8], and non-H-2-1inked Rfv-3 [9]). 
Friend  virus  complex  consists  of a  replication-competent murine leukemia 
virus designated  Friend helper virus or F-MuLV, l  and a  replication-defective 
spleen focus-forming virus designated SFFV (10,  11). In addition, some pools of 
Friend virus contain recombinant mink cell focus-forming virus(es) designated 
F-MCF.  While SFFV is required for the rapid induction of erythroblastosis in 
adult mice (12,  13), the pathogenicity of F-MuLV and F-MCF is less clear. Early 
reports using uncloned virus (10, 14, 15) indicated that Friend virus pools lacking 
SFFV caused lymphoma in BALB/c mice (16,  17),  or a disease with character- 
istics of lymphoma and erythroblastosis in Swiss mice (10). More recent experi- 
ments  using  virus  cloned  by  endpoint  dilution  in  tissue  culture  (18,  19),  or 
molecularly cloned virus (20), show that NFS/N and BALB/c mice inoculated 
with F-MuLV as neonates develop erythroblastosis. In contrast, mice of other 
strains, including DBA/2 and C57BL, are resistant to F-MuLV erythroblastosis 
(21); a recent report indicates that DBA/2 mice develop lymphoma and myeloge- 
nous leukemia several months after neonatal infection with F-MuLV (22). 
The DBA/2 resistance to erythroblastosis acts like a single dominant gene in 
backcrosses to NFS/N  (21) and BALB/c (22).  DBA/2 mice carry a  dominant 
gene on chromosome 5  that restricts the replication of MCF viruses (23),  and 
this gene, designated Rmcf, appears to be responsible for the DBA/2 resistance 
to F-MuLV erythroblastosis (J. W. Hartley and W. P. Rowe, unpublished obser- 
vations).  However, in  the same assay system, C57BL  mice do not restrict the 
growth of MCF virus, i.e.,  they carry the Rmc~ allele (23).  It was therefore of 
interest  to  investigate  the  basis  of resistance  to  F-MuLV  erythroblastosis  in 
C57BL mice. 
The experiments reported here show that C57BL mice, although resistant to 
F-MuLV erythroblastosis, develop lymphoma and myelogenous leukemia after a 
l Abbreviations used in this paper."  F-MCF,  Friend mink cell focus-forming  virus; F-MuLV, Friend 
murine leukemia  virus; LTR, long terminal  repeat; SFFV, spleen focus-forming  virus. 
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latent period of ~  160 d. Resistance of C57BL mice to erythroblastosis appears 
to be controlled by a  single  dominant  gene in  first and  second backcrosses  to 
BALB/c.  The  putative  resistance  gene  is  distinct  from  previously  identified 
Friend  virus  restriction  loci  including  H-2,  Fv-l,  Fv-2,  and  Rmcf.  Finally,  the 
C57BL  resistance  to  erythroblastosis  is  not  mediated  by a  block  to  F-MuLV 
replication. 
Materials and Methods 
Virus.  NB tropic F-MuLV that had been cloned in this laboratory by endpoint dilution 
on NFS mouse embryo cells was a kind gift from Dr. Janet w. Hartley. Virus pools were 
made from the  8th to  1 lth passage  in  NFS/N  mouse embryo cells after cloning.  No 
difference was observed in mice inoculated with different pools of F-MuLV. 
Mice.  BALB/cAnN,  C57BL/6N,  and  B10.D2NsN  mice  were  obtained  from  the 
National  Institutes  of Health  (NIH)  Small  Animal  Section.  C57BL/6J,  (BALB/c  X 
C57BL/6J)F1, and B6.C-H-7 b (C57BL/6.Fv-2  s congenic) mice were obtained from The 
Jackson Laboratory, Bar Harbor, ME. BALB/clr and BALB.B (BALB/c.H-2  b congenic) 
mice were obtained from Dr. Michael Potter, NIH. The hammertoe (Hm) marker gene 
was  bred onto the  BALB/cTr background in  this laboratory and was  used at  the  8th 
backcross  level.  This  gene  is  a  dominant  morphological  marker  resulting  in  flexion 
contraction of the toes. 
Baby mice were inoculated at 0-4 d of age; no differences were noted between mice 
inoculated on the 1st vs. 4th d after birth. In several experiments baby mice were foster 
nursed on NIH Swiss mothers; no differences were seen between mice nursed by their 
own or foster mothers. 
Hematopathology.  Inoculated mice were palpated once or twice per week after weaning 
and sacrificed when obviously diseased. At the time of autopsy, blood samples were taken 
for hematocrit and reticulocyte count. Blood films and imprints of spleen, thymus, and/ 
or lymph node were routinely stained with Wright's-Giemsa, and occasionally stained for 
hemoglobin (24)  or  leukocyte peroxidase (25).  Diseased  organs were  fixed in  Telly's 
fixative and stained with hematoxylin-eosin for light microscopy. 
Virus Assay.  XC infectious center assay was performed as described (26). 
Statistics.  Survival curves were calculated by the life table method (27). Differences in 
survival were analyzed using Kolmogorov Smirnov statistics  (28).  Correlations between 
type of disease and inherited markers in  backcross mice were analyzed by chi square 
statistics. 
Results 
Sensitive  Strains.  F-MuLV  induced  erythroblastosis  in  87%  (48/55)  of 
BALB/c mice inoculated as neonates (Table I).  No differences were observed 
between different sublines of BALB/c mice. As noted by others (18), this disease 
is  characterized  by  marked  splenomegaly,  often  with  hepatomegaly,  and  the 
absence  of enlarged  lymph  nodes  or  thymus.  Affected mice  become  severely 
anemic (mean hematocrit 23%, range 11-32%, n =  41  mice; normal hematocrit 
is 40-50% [37]). Mice with advanced disease were found to have low reticuiocyte 
counts  (mean  1.9%,  range  0.4-4.4%,  n  =  13  mice).  The  severe anemia  and 
reticulocytopenia distinguish  this disease from that caused by Friend complex, 
which leads  to reticulocytosis with either mild anemia  (FV-A) or polycythemia 
(FV-P)  (29).  Failure  of red  cell precursors  to  differentiate to  the  reticulocyte 
stage indicates a profound block to terminal differentiation in F-MuLV erythro- 
blastosis. In advanced cases, the peripheral blood shows marked aniso-poikilocy- 
tosis,  red  blood  cell  fragments,  numerous  "smudged"  or  broken  cells,  and SILVER  AND  FREDRICKSON 
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Strain 
Number of mice with given disease per 
number of mice inoculated* 
Number of mice with: 
No disease 
Erythroblas-  Lymphoma  Myeloid  Other 
tosis  leukemia  Other leukemia*  (duration of  disease| 
observation) 
Susceptible  to erythroblastosis 
BALB/c  48/55  (87)  2/55  (4)  1/55  (2)  0  4  0 
BALB.B  11/13  (85)  1/13  (8)  0/13  (0)  0  0  1(175d) 
Total  59/68  (87)  3/68  (4)  1/68  (1) 
Resistant  to erythrobiastosis 
C57BL/6  0/56  (0)  29/56  (52)  11/56  (20)  0  11  5(>180d) 
BI0.D2  0/22  (0)  9/22  (41)  4/22  (18)  1 M +  L  6  2 (>235 d) 
B6.C-H-7  b  0/16  (0)  7/16  (44)  4//16  (25)  I NEL  2  2(>lyear) 
Total  0/94  (0)  45/94  (48)  19/94  (20) 
(Susceptible  × resistant)F1 
BALB/c × C57BL/6  0/18  (0)  5/18  (28)  9/18  (50)  2 NEE  2  0 
BALB/c×BI0.D2  0/14  (0)  5/14  (36)  5/14  __(36)  INEL, 3M+L  0  0 
Total  0/32  (0)  10/32  (31)  14/32  (44) 
First backcross 
BALB/c×(BALB/c×C57BL/6)  28/73  (38)  15/73  (21)  17/73  (23)  5M+L,  4NEL, IU  3  0 
BALB/c × (BALB/c × B10.D2)  29/71  (41)  33/71  (46)  4/71  (6)  0  5  0 
Total  57/144  (40)  48/144  (33)  21/144 (15) 
Second backcross 
BALB/c×resistantBCImales  I  35/89  (39)  22/89  (25)  15/89  (17)  3M+L,  1U  12  1(308d) 
Balb/c × susceptible  BCI male  ~  12/13  (92)  1/13  (8)  0/13  (0)  0  0  0 
* Numbers in parentheses are percentages. 
:~ M + L, myelogenous leukemia plus lymphoma; NEL, nonerythroid leukemia (mice with grossly enlarged spleen and lymph nodes but histology 
not done or inadequate for more preceise diagnosis);  U, undifferentiated leukemia involving splenic red pulp. 
! About half the mice in this category were found dead and too decomposed for diagnosis;  most of the others had pneumonia. This incidence 
of pneumonia is much higher than for other mice in our animal colony and may result from immunosuppresslve effects on F-MuLV. One 
C57BL/6 mouse had glomerulonephritis and one (BALB/c × C57BL/6)F1 mouse bad endometritis. 
I This group comprises the progeny of seven first backcross  males who eventually developed lymphoma or myelogenous leukemia. 
This group comprises the progeny of one first backcross male who eventually developed erythroblastosis. 
basophilic and polychromatophilic erythroblasts (Fig.  I). The splenic red pulp is 
greatly expanded with erythroid precursors (Fig.  1), and similar cells frequently 
infiltrate the hepatic sinusoids. The median latency before detection of erythro- 
blastosis in BALB/c mice was 85 d (range 49-220 d). 
3 of 55 BALB/c mice developed other hematopoietic neoplasms: 2 lymphomas 
(detected on days 129 and 148) and 1 myelogenous leukemia (on day 150).  In 
addition, of five BALB/c  mice that  were transfused after developing typical 
erythroblastosis, one yielded a  transplantable lymphoma. Thus, while the vast 
majority of BALB/c mice develop erythroblastosis, occasional mice come down 
with  other  hematopoietic  neoplasms,  usually  after  longer  latent  periods. 
BALB/c mice congenic for the H-2 ~ allele from C57BL/6 (BALB.B) responded 
like BALB/c mice (Table I), indicating that 1-1-2 b does not confer resistance to 
erythroblastosis. 
Resistant Strains.  Of 56 C57BL/6 mice inoculated as neonates with F-MuLV, 
none developed typical  erythroblastosis.  However,  29  (52%)  developed lym- 
phoma. Mice with lymphoma had splenomegaly with enlarged lymph nodes and/ 
or thymus and neoplastic cells with morphologic characteristics of lymphoblasts. 
Within the spleen, a tumor involved and expanded the white pulp. The hema- 
tocrit in cases of lymphoma was usually only slightly depressed (mean 40.5%, 
range 29-52%, ~ -- 21  mice). In advanced cases, lymphoblasts were seen in the 496 SILVER AND  FREDRICKSON  497 
peripheral blood (Fig.  1). When the liver was infiltrated, lymphoblasts accumu- 
lated more in periportal than in sinusoidal areas. The thymus was grossly enlarged 
in only 6 of 29 cases and microscopically involved in 6 others. This predominantly 
nonthymic localization of F-MuLV lymphomas in C57BL/6 mice contrasts with 
the typical thymic lymphoma of AKR  mice and  mice infected with Moioney 
virus.  Differentiation of lymphoma from erythroblastosis usually was clearcut 
based on lymph node enlargement, nearly normal hematocrit and microscopic 
examination of lymphoid organs. 
11 of 56 C57BL/6 mice developed myelogenous leukemia. This diagnosis was 
made when: (a) the spleen was enlarged (>0.5 g); (b) histology showed hypertro- 
phied red pulp containing predominantly immature myeioid or monocytic cells; 
and (c) there was no obvious infection to account for a leukemoid reaction. Mice 
with myelogenous leukemia (C57BL  as  well as  crosses involving C57BL,  see 
below) usually had dark red spleens ~0.6-0.8  g, and enlarged greenish lymph 
nodes (chloroleukemia). This contrasts with the larger (-~ 1 g) pale spleens of 
mice with erythroblastosis and the lack of pigmentation of enlarged lymph nodes 
in mice with lymphoma. The hematocrit in cases of myelogenous leukemia was 
usually only slightly depressed (mean 33.0, range 8-55, n = 22 mice). Microscopic 
examination of myeloid leukemias revealed  large  variation  in  the  degree of 
granulocyte maturation or monocytoid morphology. In some cases,  immature 
myeloid cells infiltrated the thymus; rarely was this extensive enough to cause 
gross thymic enlargement. When the liver was involved, immature cells tended 
to infiltrate periportal rather than sinusoidal areas. 
A few mice with myelogenous leukemia were atypical in that they had severe 
anemia and large numbers of erythroid precursors in the splenic red pulp. If 
there was  no apparent  block to  terminal differentiation of red cells  (i.e.,  the 
reticulocyte count was elevated), such mice were deemed to have myelogenous 
leukemia with  "reactive"  erythroid hyperplasia.  2  of the  11  cases of myeloid 
leukemia in C57BL/6 mice fell into this category. 
B10.D2  mice had the same pattern of disease as C57BL/6  mice (Table  I), 
indicating that a gene (or genes) other than H-2 b is responsible for resistance to 
erythroblastosis.  Similarly,  C57BL/6  mice congenic for Fv-2 s (B6.H-7 b)  were 
resistant to erythroblastosis (Table  I),  indicating that a  gene (or genes) other 
than Fv-2 r can prevent the development of erythroblastosis. The median latent 
period for lymphoma among these resistant strains was 119 d (range 54-319 d, 
n  =  38  mice),  compared  with  168  d  (range  64-274  d,  n  =  17  mice)  for 
myelogenous leukemia. 
F1,  First and Second Backcross Mice.  (BALB/c ×  C57BL/6)F1  and (BALB/c 
x  B10.D2)F1  mice were resistant to erythroblastosis (0/32 mice) but developed 
late myelogenous and lymphoid neoplasms (30/32 mice) after neonatal inocula- 
tion with F-MuLV (Table I). The incidence of myelogenous leukemia was higher 
among F1 than C57BL/6 mice (14/32 vs. 11/56), and the latency for develop- 
FIGURE  1.  Peripheral  blood and  splenic  histology  of mice  with  F-MuLV  hematopoietic 
neoplasms.  (A) blood, (B) splenic red pulp from BALB/c mouse  with erythroblastosis,  (C) 
blood, (D) splenic white pulp from C57BL/6 mouse with lymphoma, (E) blood, and (F) splenic 
red pulp from C57BL/6 mouse with myelogenous leukemia. 498  RESISTANCE TO  FRIEND  HELPER  VIRUS  ERYTHROBLASTOSIS 
ment of clinically obvious disease was longer (median 210 vs. 157 d; Fig. 2). 
About 40% (57/144) of F-MuLV-inoculated mice from the first backcross to 
BALB/c developed erythroblastosis (Table I). This includes 4 mice with typical 
erythroblastosis plus early thymic lymphoma and 2  mice with erythroblastosis 
plus myelogenous leukemia. The latter mice had large lymph nodes filled with 
myeloid precursors, large spleens filled with myeloid and erythroid precursors, 
severe anemia, and reticulocytopenia. ,-~54% (78/144)  of first backcross mice 
developed exclusively nonerythroid hematopoietic neoplasms (Table  I).  Diag- 
nosis  was uncertain or unobtainable in the remaining 6%  (9/144)  of mice: 7 
mice were found dead and too decomposed for diagnosis (on days 90,  102  [3 
mice], 103,  150, and 167);  1 mouse died accidently (on day 97); and one mouse 
developed anemia and splenomegaly with immature cells confined to the red 
pulp  (early  erythroblasts?).  These  data  suggest  a  single  dominant  gene  for 
resistance to erythroblastosis; i.e., the incidence of erythroblastosis in backcross 
mice (40%) is about half that in BALB/c mice (87%). 
The latency for erythroblastosis in first backcross mice (median  106  d) was 
slightly but significantly longer than for BALB/c mice (median 85 d) (P < 0.005, 
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FIGURE 2.  Disease-free survival in BALB, C57BL, (BALB X C57BL)F1, and first backcross 
mice inoculated with F-MuLV as neonates. (0, O) erythroblastosis, (&, A) lymphoma, (m, I-'1) 
myeloid leukemia, (0, O) nonerythroid leukemia (see legend to Table I). Vertical bars indicate 
mice with another disease or which were healthy at last follow-up. Adjacent symbols indicate 
mice with dual diagnoses. Each symbol or pair of symbols corresponds to one mouse. BCI-E, 
first backcross mice with erythroblastosis; BCI-L, M, first backcross mice with lymphoma or 
myelogenous leukemia. SILVER  AND  FREDRICKSON  499 
Kolmogorov-Smirnov statistics,  two-tailed  test).  This  suggests  that  additional 
genes in the C57BL/6 background affect the latency but not the type of disease 
induced by F-MuLV. 
If one dominant gene controlled resistance to erythroblastosis, resistant first 
backcross males mated to BALB/c females should segregate approximately equal 
numbers of sensitive and  resistant progeny.  The incidence of erythroblastosis 
among the second backcross progeny of 7 first backcross males who eventually 
died of nonerythroid neoplasias was 39% (35/89 mice) (Table I), very similar to 
the  incidence  of erythroblastosis  in  first  backcross  mice.  The  proportion  of 
progeny developing erythroblastosis from each male tested was not significantly 
different  from  the  overall  proportion  of  39%  (not  shown).  In  contrast,  the 
incidence of erythroblastosis among second backcross progeny of a first backcross 
male who developed erythroblastosis was 92%  (12/13).  Thus, when mated to 
BALB/c,  first  backcross  mice that  are  resistant  to erythroblastosis appear  to 
segregate susceptible and resistant offspring, whereas susceptible first backcross 
mice produce susceptible offspring. Taken together, the results of the first and 
second backcrosses strongly suggest that C57BL mice carry a  single dominant 
gene for resistance to erythroblastosis. 
Difference from Other Genes Known to Affect  Friend Virus.  H-2 does not control 
the type of disease induced by F-MuLV since BALB.B and B 10.D2 mice respond 
like BALB/c and C57BL/6  mice, respectively.  Furthermore, a  gene linked to 
14-2 does not determine resistance to F-MuLV erythroblastosis,  since no corre- 
lation  was  observed  between  inheritance  of H-2 b and  type  of disease  in  73 
BALB/c ×  (BALB/c ×  C57BL) backcross mice (Table II). 
Fv-1 would not be expected to play a role in these experiments since the virus 
TABLE  II 
Lack of Correlation  Between Type of Leukemia and 1-1-2, Gpd (Fv-1), 
Hm (Rmcf), and Coat Color Loci in BALB × (BALB × C57BL) 
Backcross Mice 
Number of mice with: 
Lymphoma 
Genotype of  and/or  Erythro-  X  ~ 
backcross mice  myelogen-  blastosis 
ous leuke- 
mia 
/-/-2  ba  21  9  2.56 
H-2  aa  19  17 
Gpd  °b  4  6  .80 
Gpd  hh  6  4 
NS* 
NS 
++  15  18  2.87  NS 
Hm  +  20  10 
Cc  54  38  .76  NS 
cc  54  46 
Bb  25  20  2.61  NS 
bb  25  11 
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used was NB tropic and both BALB/c and C57BL mice carry the Fv-1 b allele. 
To rule out a gene closely linked to Fv-1, we tested backcross mice for inheritance 
of Gpd-1, which is linked to Fv-1 (30).  No correlation was seen between inherit- 
ance of Gpd-1 ~ from C57BL and resistance to erythroblastosis (Table II). 
It seems unlikely that Fv-2 determines resistance to F-MuLV erythroblastosis 
because B6.C-H-7 b (Fv-2  ~ congenic) mice are resistant to  erythroblastosis and 
resistance appears to be controlled by a single gene. Furthermore, Fv-2 resistance 
to Friend complex disease is recessive, while the resistance to erythroblastosis 
described here is dominant. However, to be sure that we were not dealing with 
a new manifestation of the Fv-2 r gene, backcross mice were tested for inheritance 
ofMod-1, linked to Fv-2 (31). The incidence of erythroblastosis among backcross 
mice that inherited the C57BL Mod-1  allele (and which therefore had a  90% 
probability of inheriting Fv-2 ~) was 36% (5/14), not significantly different from 
the overall incidence of 40%.  Therefore Fv-2 r does not control  resistance to 
erythroblastosis in this system. 
Rmcf,  a  gene closely linked to Hm  on chromosome 5,  controls resistance to 
erythroblastosis in crosses with DBA/2 mice (J. Hartley and W.  Rowe, unpub- 
lished observations). (This gene is therefore probably the same as the recently 
reported Fv-6 [22].) Even though both BALB/c and C57BL are Rmcf (23), we 
tested for correlation between inheritance of this region of chromosome 5 from 
C57BL  and  resistance to  erythroblastosis using the Hm  marker.  The  data in 
Table II show no significant correlation between inheritance of the Hm region 
of chromosome  5  from  the  C57BL  grandparent  and  type  of leukemia.  No 
association was seen between resistance to erythroblastosis and inheritance of 
nonalbino (C) or black coat color (B) from C57BL/6 mice (Table II). 
Resistance  to  F-MuLV  Erythroblastosis  Is  Not  Mediated  by  Inhibition  of F-MuLV 
Replication.  As shown in Table III, we found no strain difference in titer of F- 
MuLV in the spleen, thymus, or lymph node of BALB/c, C57BL/6,  (BALB/c 
× C57BL/6)F1  or backcross mice either early or late after infection. 
Discussion 
The data presented here provide evidence that C57BL  mice carry a  single 
dominant gene for resistance to  F-MuLV  erythroblastosis.  The  fact that  the 
incidence of erythroblastosis is slightly less than 50% in first and second backcross 
mice is probably due to loss  of some susceptible mice to other diseases. In this 
regard  it  is  important  to  note  that  "--10%  of BALB/c  mice  develop  other 
hematopoietic neoplasms, and the latent period for development of erythroblas- 
tosis is longer in backcross mice than in BALB/c mice. Therefore backcross mice 
which inherit susceptibility to erythroblastosis should have a greater chance than 
BALB/c mice of developing other diseases before coming down with erythro- 
blastosis.  In addition, our incidence figures for erythroblastosis may be under- 
estimates due to the exclusion of several mice which died without diagnosis early 
after inoculation (when erythroblastosis is  the most common cause of death). 
<50%  incidence of erythroblastosis  in  backcross mice could also  result  from 
additional incompletely dominant resistance genes in  the C57BL  background. 
Analysis of susceptibility to erythroblastosis in higher backcrosses may clarify this 
situation. SILVER  AND  FREDRICKSON  501 
TABLE  III 
Titer of F-MuLV in Lymphoid Organs of Susceptible and Resistant Mice Inoculated as Neonates 
Num-  XC titer* in: 
ber of  Days 
after in-  Diagnosis  Lymph 
Strain  mice  oculation  Spleen  Thymus 
tested  node 
Preleukemic 
BALB/c 
C57BL/6 
BALB x  C57BL/6 
Leukemic 
BALB/c 
C57BL/6 
C57BL/6 
BALB x  C57BL/6 
BALB x  (BALB x 
C57BL/6) 
BALB X (BALB x 
C57BL/6) 
BALB x  (BALB x 
C57BL/6) 
7  33-64  Healthy  5.6 ±  0.5  5.7 ±  0.3  ND 
7  33-73  Healthy  5.6 ±  0.6  5.7 _  0.3  ND 
6  30-93  Healthy  5.3 ±  0.6  5.6-  0.3  ND 
5  64-161  E*  6.0 ±  0.8  6.0 -4- 0.2  !  ND 
1  157  L*  6.4  6.4  ND 
1  266  M  ¢  ND  ND  6.2 
1  128  L  6.3 !  ND  6.3 I 
4  104-169  L  6.2 +  0.5  ND  6.1  ±  0.6  ~ 
2  106-144  E  6.3 +  0.4  ND  ND 
1  169  M  5.8  ND  ND 
* XC titer expressed as mean +  standard deviation of log~0 (number of infectious centers per  10 7 
cells). 
* E, erythroblastosis; L, lymphoma; M, myelogenous leukemia. 
0 Three mice only. 
I Mixture of spleen and lymph node cells. 
I Two mice only. 
The data presented here also show that  dominant  resistance of C57BL mice 
to F-MuLV erythroblastosis is genetically distinct from previously reported genes 
affecting susceptibility to  Friend  virus including H-2  (6),  the H-2-1inked genes 
Rfv-1  (7)  and  Rfv-2  (8),  Fv-1  (3,  4),  Fv-2  (3,  4),  and  Rmcf (23).  The  C57BL 
resistance to F-MuLV erythroblastosis is also phenotypically different from Fv- 
4, a  gene that restricts replication  of F-MuLV (2), and from Rfv-3,  a  gene that 
controls recovery from viremia in mice inoculated with Friend complex as adults 
(9) and which is not manifest in crosses between C57BL and BALB.B (32).  We 
suggest the name Fhe for this new locus controlling susceptibility to Friend helper 
virus erythroblastosis,  with  C57BL carrying  the  dominant  resistant  Fhe r allele 
and BALB/c the sensitive Fhe  s allele. 
The mechanism of Fhe  r resistance is not understood. It appears to act at a step 
in leukemogenesis distal to replication of the input  F-MuLV. It is possible that 
Fhg prevents the generation or replication of an erythroblastosis-specific recom- 
binant virus. MCF viruses are uniformly present in NFS/N mice inoculated with 
F-MuLV as neonates, and appear to be necessary for development of erythrob- 
lastosis since Rmcf  ~ prevents  or delays erythroblastosis  in  these  mice.  We and 
others (21) have  not found  MCF viruses in  F-MuLV inoculated  C57BL mice, 
even though  these mice are  not resistant  to the replication  of MCF viruses in 
vitro (23). If resistance to erythroblastosis in C57BL mice is mediated by failure 
to  generate  the  right  MCF  virus,  it  is  important  to  recall  that  resistance  is 
dominant  in crosses with BALB/c, and therefore cannot be due to absence of 
the correct host sequence for recombination. Further experiments are in progress 502  RESISTANCE  TO  FRIEND HELPER VIRUS ERYTHROBLASTOSIS 
to test whether genes in the C57BL background that interfere with the genera- 
tion of MCF viruses in vivo are responsible for resistance to erythroblastosis. 
Another possible mechanism of Fhe r resistance is at the level of the immune 
response. C57BL mice are reportedly resistant to the immunosuppressive effects 
of Friend complex (5).  Immunosuppression  in  BALB/c  mice could block  an 
immune response to transformed erythroblasts or remove a competing lymphoid 
target for transformation.  In  this  regard it  is  interesting that an isolate of F- 
MuLV  which  usually  caused  lymphatic  leukemia  in  BALB/c  mice  induced 
erythroleukemia when the mice were thymectomized and treated with antilym- 
phocyte serum (33).  However, immunosuppression induced by Friend complex 
is reported to  be recessive in  crosses with C57BL  mice (5),  whereas the Fhe r 
resistance described here is dominant. 
A third possible mechanism of  Fhe  r resistance is through control of some aspect 
oferythroid differentiation that affects susceptibility to erythroid transformation. 
This type of mechanism has been reported to determine resistance at Fv-2 (34). 
Recent studies point to the importance of the virus long terminal repeat (LTR) 
in determining tissue tropism and target for transformation of several different 
retroviruses (38,  39).  These studies raise the possibility that Fhe r controls the 
replication  of input  or  recombinant  MuLV  in  specific  target  cells,  perhaps 
through interaction with the viral LTR. 
Mouse strain differences in the type of leukemia induced by Graffi leukemia 
virus were reported several years ago (35), and a similar phenomenon has been 
reported for long latency leukemia viruses in chickens (36). Investigation of host 
genes affecting the target cell for leukemic transformation should complement 
studies of viral determinants of target cell specificity and provide new insights 
into post-input virus replication steps in viral leukemogenesis. 
Summary 
NB tropic Friend murine leukemia virus (F-MuLV) replicates equally well in 
BALB/c and C57BL mice inoculated as neonates but causes almost exclusively 
erythroblastosis in BALB/c mice and nonerythroid (lymphoid and myelogenous) 
leukemias in C57BL mice. The C57BL resistance to erythroblastosis appears to 
be  controlled  by  a  single  dominant  gene  in  first  and  second  backcrosses  to 
BALB/c. This resistance to erythroblastosis is distinct from other genes known 
to affect susceptibility to Friend virus including Fv-1, Fv-2, H-2, Rfv-3, Fv-4, and 
Rmcf  We suggest the name Fhe for the new gene controlling susceptibility to 
Friend helper virus erythroblastosis. 
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